Variables | Daily analysis | Global analysisa | |||
---|---|---|---|---|---|
Day | Low-target group | High-target group | P | P | |
Number of patients treated with vasoactive drugs; n | D0 | 219 | 248 | NA | NA |
D1 | 197 | 231 | NA | ||
D2 | 122 | 158 | NA | ||
D3 | 76 | 112 | NA | ||
D4 | 53 | 78 | NA | ||
D5 | 41 | 56 | NA | ||
Daily dose of norepinephrine per patient (mg/kg); mean (SD)/n | D0 | 37.94 (48.59)/219 | 57.48 (86.91)/248 | 0.003 | |
D1 | 70.09 (97.34)/197 | 94.19 (163.35)/231 | 0.06 | ||
D2 | 63.4 (108.37)/122 | 57.89 (75.5)/158 | 0.632 | ||
D3 | 60.03 (98.21)/76 | 50.19 (78.84)/112 | 0.468 | ||
D4 | 64.39 (95.24)/53 | 47.3 (73.39)/78 | 0.273 | ||
D5 | 46.89 (75.02)/41 | 47.58 (73.36)/56 | 0.964 | ||
Daily dose of fentanyl per patient (µg/kg); mean (SD)/n | D0 | 11.04 (14.43)/209 | 12.22 (20.23)/236 | 0.476 | 0.665 |
D1 | 14.23 (18.48)/191 | 14.66 (21.55)/220 | 0.827 | ||
D2 | 11.64 (14.96)/120 | 14.15 (21.34)/150 | 0.258 | ||
D3 | 14.51 (17.07)/71 | 15.68 (21.71)/103 | 0.692 | ||
D4 | 18.12 (18.93)/51 | 17.07 (22.59)/71 | 0.781 | ||
D5 | 20.43 (21.8)/39 | 19.96 (27.76)/52 | 0.929 | ||
Daily dose of midazolam per patient (mg/kg); mean (SD)/n | D0 | 1.28 (1.39)/212 | 1.43 (1.33)/238 | 0.449 | 0.613 |
D1 | 1.72 (1.64)/184 | 1.71 (1.55)/215 | 0.710 | ||
D2 | 1.56 (1.43)/115 | 1.59 (1.41)/143 | 0.243 | ||
D3 | 1.81 (1.5)/70 | 1.61 (1.54)/104 | 0.584 | ||
D4 | 1.73 (1.45)/49 | 1.61 (1.57)/68 | 0.967 | ||
D5 | 1.91 (1.69)/36 | 2.18 (1.91)/46 | 0.932 | ||
Daily dose of propofol per patient (mg/kg); mean (SD)/n | D0 | 10.34 (19.52)/11 | 14.3 (21.41)/19 | 0.245 | 0.734 |
D1 | 38.61 (26.85)/8 | 13.88 (18.02)/13 | 0.01 | ||
D2 | 0 | 12.2 (15.08)/11 | |||
D3 | 0 | 8.16 (7.41)/7 | |||
D4 | 8.57 (0.34)/2 | 6.86 (8.37)/2 | |||
D5 | 6.71 (NA)/1 | 5.41 (5.86)/4 | 0.8 | ||
Patients treated with neuromuscular blockers; n (%) | D0 | 86/219 (39.3%) | 102/248 (41.1%) | 0.683 | 0.726 |
D1 | 73/197 (37.1%) | 83/231 (35.9%) | 0.81 | ||
D2 | 41/122 (33.6%) | 45/158 (28.5%) | 0.357 | ||
D3 | 29/76 (38.2%) | 24/112 (21.4%) | 0.012 | ||
D4 | 21/53 (39.6%) | 20/78 (25.6%) | 0.09 | ||
D5 | 21/41 (51.2%) | 17/56 (30.4%) | 0.038 |